• Explore /
  • Poster
  • / A phase II, open label study of tucatinib (ONT-380) combined with trastuzumab in patients with HER2+ metastatic colorectal cancer (mCRC)(MOUNTAINEER).

A phase II, open label study of tucatinib (ONT-380) combined with trastuzumab in patients with HER2+ metastatic colorectal cancer (mCRC)(MOUNTAINEER).

Abstract Poster

Authors

John Strickler

John H. Strickler

Duke Cancer Institute, Duke University Medical Center, Durham, NC

John H. Strickler , Donna Niedzwiecki , Tyler Zemla , Andrea Cercek , Marwan Fakih , Kimmie Ng , Federico Augusto Sanchez , Christina Sing-Ying Wu , Scott Peterson , Lorelei Bandel , Axel Grothey , Tanios S. Bekaii-Saab

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Colorectal) Cancer

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer–Advanced Disease

Clinical Trial Registration Number

NCT03043313

Citation

J Clin Oncol 35, 2017 (suppl; abstr TPS3624)

DOI

10.1200/JCO.2017.35.15_suppl.TPS3624

Abstract #

TPS3624

Poster Bd #

244a

Abstract Disclosures

Similar Posters

First Author: John H. Strickler

First Author: John H. Strickler

First Author: Tanios S. Bekaii-Saab

First Author: Samuel A. Jacobs